Wren Capital
VC Fund
London, United Kingdom
Wren Capital is a VC fund in London focused on Biotechnology and Health Care. Wren is an angel investor in science, engineering and software. They founded Wren in 2011 and have invested in 50 companies so far.Wren is well known in the early stage investment community and has co-invested with a wide range of both angel and institutional investors. From software and semiconductors to genome editing, and from medical devicesto satellites, they are interested in sectors where technical ingenuity and hard work can produce long term value. They look for people with a deep understanding of their markets. The founders they invest in are smart and they get things done.Wren typically invests £50,000 to £200,000 per funding round. Difficult problems take time to solve, so they are patient with their investments. Their aim is to get deals done and they take a pragmatic approach to doing so.
- Total investments:
- 34
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Wren Capital invests in
Stages Wren Capital invests in
Countries Wren Capital invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $1.6M–$5M
- Series A
- $2M–$33M
- Venture - Series Unknown
- $1.1M–$8.9M
Investment Focus
Industry
- Biotechnology 15 (44%)
- Health Care 8 (24%)
- Medical 5 (15%)
- Medical Device 5 (15%)
- Genetics 3 (9%)
Stage
- Seed 12 (35%)
- Series A 7 (21%)
- Venture - Series Unknown 6 (18%)
- Funding Round 3 (9%)
- Angel 2 (6%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Rajat Malhotra
Managing Partner
|
Managing Partner | Total investments: 2 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Singular Photonics is a startup that creates SPAD-based image sensors. | $2.2M / Seed / Aug 19, 2026 | ||
| SenseAIsoftware dramatically speeds up image acquisition while reducing sample damage from high-energy electron beams, offering up to 100x improvements in efficiency without loss of image integrity. | Seed / Sep 08, 2025 | ||
| Monument Therapeutics is a biotechnology company intended to develop drugs to treat serious diseases of the central nervous system. | $1.1M / Venture - Series Unknown / Feb 25, 2025 | ||
| Spotta is the creator of an ultra-low-power insect monitoring sensor for detecting bed bug infestations. The company's sensor is battery-powered, allowing users to be notified whenever bed bugs are detected and analyzing the detection to ensure users are only notified about genuine incidents, allowing customers to prevent bed bugs fromentering the room and make treatment easier and less expensive. | $3.8M / Series A / Dec 15, 2023 | ||
| MitoRx Therapeutics is a biotechnology company developing novel therapeutics that reverse mitochondrial dysfunction. | $5M / Seed / Dec 13, 2023 | ||
| Bastion Therapeutics is a preclinical stage biotechnology startup that uses proprietary platform technology to boost Tregs for the immune system | $840K / Sep 12, 2023 | ||
| PharmEnable has developed a rapid and cost effective way to identify better chemical starting points to drive the discovery of vital new medicines. | $7.5M / Seed / May 22, 2023 | ||
| MitoRx Therapeutics is a biotechnology company developing novel therapeutics that reverse mitochondrial dysfunction. | Seed / Apr 25, 2022 | ||
| Adapttech is a biomedical company that creates innovative, smart, and wearable technologies to assist people with physical disabilities in improving their quality of life. It aims to provide clinicians with better socket fitting and monitoring methods in order to improve the quality of life for people who have lost a lower limb. | $2.9M / Series A / Apr 06, 2022 | ||
| Centauri Therapeutics is a UK-based biotechnology company focused on the discovery and development of novel molecules targeting life threatening diseases. The Alphamer technology is based on "programmable immunity" in which chemically synthesised molecules redirect naturally occurring antibodies to selected pathogens to fight theinfection. The molecules have two distinct parts: one end binds a cell-surface target on the pathogen using an aptamer whereas the other end presents specific epitopes that attach to the circulating antibodies. It has been demonstrated that Alphamers have the potential to redirect pre-existing antibodies to bacteria in a specific manner and trigger an immediate antibacterial immune response, so clearing the infection. Centauri Therapeutics’ strategy is to redirect naturally occurring antibodies to target disease. Centauri Therapeutics' unique Chemistry Platform provides a flexible scaffold to enable the synthesis of specific Alphamers. These are bifunctional molecules which present a selective cell binding moiety as well as an epitope that recruits pre-existing antibodies, resulting in cell killing. Centauri Therapeutics believes their technology is widely applicable in the treatment of life threatening infectious diseases. Companies with an interest in accessing Centauri’s Alphamer technology or with an interest in one of their current projects, are warmly encouraged to contact them to discuss partnering opportunities. In order to drive success in the important area of immuno-oncology, Centauri Therapeutics has established a joint venture, Avvinity Therapeutics, with Horizon Discovery in March 2016. Avvinity combines Centauri’s Alphamer Technology with the gene editing and oncology expertise of Horizon. In addition to Centauri Therapeutics' immuno-oncology joint venture, Centauri maintains a strong network of collaborators in the areas of aptamer selection, drug discovery, chemistry and immunology. | $32.6M / Series A / Feb 16, 2022 | ||
| See all 34 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Wren Capital invest in?
Wren Capital invests primarily in Biotechnology, Health Care and Medical startups, most often at Seed and Series A stage. Most of the 34 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Wren Capital's check size?
Wren Capital typically joins rounds of $1.6M–$5M at Seed, $2M–$33M at Series A and $1.1M–$8.9M at Venture - Series Unknown. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Wren Capital participates in.
How do I contact Wren Capital?
Public channels for Wren Capital include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Wren Capital?
The team at Wren Capital includes Rajat Malhotra (Managing Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
